Staphylococci, Catecholamine Inotropes and Hospital-Acquired Infections

Primrose P E Freestone; Noura Al-Dayan; Mark Lyte

doi:10.1007/978-3-319-20215-0_8

Staphylococci, Catecholamine Inotropes and Hospital-Acquired Infections

Adv Exp Med Biol. 2016:874:183-99. doi: 10.1007/978-3-319-20215-0_8.

Authors

Primrose P E Freestone¹, Noura Al-Dayan², Mark Lyte^{3

4}

Affiliations

¹ Department of Infection, Immunity and Inflammation, School of Medicine, University of Leicester, University Road, Leicester, LE1 9HN, UK. ppef1@le.ac.uk.
² Department of Infection, Immunity and Inflammation, School of Medicine, University of Leicester, University Road, Leicester, LE1 9HN, UK.
³ Department of Pharmacy Practice, School of Pharmacy, Texas Tech University Health Sciences Center, 3601 4th Street, MS 8162, Lubbock, TX, 79430, USA.
⁴ Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, 50011, USA.

PMID: 26589219
DOI: 10.1007/978-3-319-20215-0_8

Abstract

Patients in hospital intensive care units have long been recognized as being at high risk for developing infections from bacteria, fungi, and viruses from within the hospital locality. Risk factors for development of nosocomial infections have usually focussed on the patient's physical condition and the number and type of invasive medical procedures administered. Using the staphylococci as its focus, this chapter presents recent evidence that some of the medications routinely used in the treatment of acutely ill patients may also be a risk factor for the development of nosocomial infections.

Publication types

Review

MeSH terms

Animals
Anti-Bacterial Agents / pharmacology
Biofilms
Catecholamines / pharmacology*
Cross Infection / etiology*
Humans
Intensive Care Units
Risk Factors
Staphylococcus / drug effects*
Staphylococcus / physiology

Substances

Anti-Bacterial Agents
Catecholamines